Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Organic Chemistry,Drug Discovery,Pharmacology,General Medicine
Reference28 articles.
1. New PARP targets for cancer therapy;Vyas;Nat. Rev. Canc.,2014
2. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets;Krishnakumar;Mol. Cell.,2010
3. Poly ADP-ribosylation and cancer;Miwa;Canc. Sci.,2001
4. PARP inhibitors: its role in treatment of cancer, Chin;Chen;J. Canc.,2011
5. PARP inhibition and synthetic lethality in ovarian cancer;Eskander;Expet Rev. Clin. Pharmacol.,2014
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects;European Journal of Medicinal Chemistry;2024-02
2. Design and synthesis of the first PARP-1 and proteasome dual inhibitors to treat breast cancer;European Journal of Medicinal Chemistry;2024-01
3. Indirubin derivatives as bifunctional molecules inducing DNA damage and targeting PARP for the treatment of cancer;European Journal of Medicinal Chemistry;2023-12
4. Small molecule tractable PARP inhibitors: Scaffold construction approaches, mechanistic insights and structure activity relationship;Bioorganic Chemistry;2023-12
5. Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities;European Journal of Medicinal Chemistry;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3